Malignant News and Research

RSS

Manipulating T cells with iPSC techniques could help develop effective immune therapies

The human body contains immune cells programmed to fight cancer and viral infections, but they often have short lifespans and are not numerous enough to overcome attacks by particularly aggressive malignancies or invasions.

4 Jan 2013

Ulcerative colitis impairs work capacity

Patients with ulcerative colitis have higher rates of sick leave or disability pension than the general population, show findings published in Gastroenterology.

28 Dec 2012

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.

27 Dec 2012

Cancer-associated inflammation boosts ADAR1 enzyme activity

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence.

25 Dec 2012

Computed tomography-induced cancer risk may be overstated

Clinicians should be careful not to overemphasize the risk for radiation-induced cancer when counseling patients on undergoing surveillance computed tomography imaging, caution US scientists.

24 Dec 2012

Comorbidity could alter joint arthroplasty prognosis

The long-term outcome of hip and knee arthroplasty may be significantly influenced by comorbidity, suggest results from a large register-based study of over 96,000 osteoarthritis patients.

22 Dec 2012

New work on Akt's role in cancer stem cell biology

The protein kinase Akt is a key regulator of cell growth, proliferation, metabolism, survival, and death. New work on Akt's role in cancer stem cell biology from the lab of senior author Honglin Zhou, MD, PhD and Weihua Li, co-first author, both from the Center for Resuscitation Sciences, Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, and Xiaowei Xu, Department of Pathology and Laboratory Medicine, appears in Molecular Cell.

21 Dec 2012

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors and are useful in cancer therapy. They can also serve as potential biomarkers for early cancer detection. In a new issue of Cancer Biomarkers, investigators report on non-coding miRNAs as appealing biomarkers for malignancy.

20 Dec 2012

Enlarged lymph nodes may warn of cancer

Enlarged lymph nodes are a marker for both occult cancer and a long-term risk for malignancy, confirms research published in the British Journal of Haematology.

19 Dec 2012

PRSS3 enzyme linked to aggressive prostate cancer

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.

18 Dec 2012

Preop features predict pathology of small renal masses

Researchers have identified preoperative clinical and tumor characteristics that predict the risk for malignancy in patients undergoing partial nephrectomy for small renal masses.

17 Dec 2012

Dantrolene shows promise for treating DMD

A muscle relaxant called dantrolene used for treating malignant hyperthermia boosts the activity of therapies currently being developed to treat the genetic disorder Duchenne muscular dystrophy (DMD), show study findings.

17 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

MicroRNA-218 especially low in medulloblastoma

Between the blueprint of the genome and the products of its expression lie microRNAs, which can boost or lower the rate at which genes become stuff. In fact, many cancers use microRNA to magnify the expression of faulty genes or shrink the expression of helpful genes that would otherwise suppress tumors. A University of Colorado Cancer Center study published in the December issue of the Journal of Biological Chemistry shows that in medulloblastoma, a malignant brain tumor of children, microRNA-218 is especially low.

14 Dec 2012

Massage could ease distress of brain cancer

Massage therapy can significantly reduce distress levels in individuals with brain tumors, indicating its potential use to improve quality of life in this population, report US researchers.

13 Dec 2012

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

13 Dec 2012

Opioids already in the body can enhance malignant tendencies of human cancer cells

A study led by University of Chicago researcher Patrick A. Singleton, Ph.D. and published in the journal Anesthesiology has shown that, even without the addition of further opioids such as morphine, opioids already in the body can enhance the malignant tendencies of human cancer cells.

13 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

Oncogene-induced senescence could play a key role in future cancer therapy

Cell aging, or cellular senescence, has an important role in the natural physiological response to tumor development. Activated oncogenes are able to induce senescence, and recent findings have suggested that oncogene-induced senescence (OIS) could play a key role in future cancer therapy.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Malignant News and Research

Manipulating T cells with iPSC techniques could help develop effective immune therapies

Ulcerative colitis impairs work capacity

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Cancer-associated inflammation boosts ADAR1 enzyme activity

Computed tomography-induced cancer risk may be overstated

Comorbidity could alter joint arthroplasty prognosis

New work on Akt's role in cancer stem cell biology

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

Enlarged lymph nodes may warn of cancer

PRSS3 enzyme linked to aggressive prostate cancer

Preop features predict pathology of small renal masses

Dantrolene shows promise for treating DMD

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

MicroRNA-218 especially low in medulloblastoma

Massage could ease distress of brain cancer

Doctors should use different therapies when treating older and younger patients with CLL

Opioids already in the body can enhance malignant tendencies of human cancer cells

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Oncogene-induced senescence could play a key role in future cancer therapy

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News